Silexion Therapeutics Corp Warrant (SLXNW)
Company News
Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration
Silexion Therapeutics demonstrated successful systemic distribution of SIL204 to major pancreatic cancer metastatic sites in preclinical studies, showing tumor burden reductions across liver, peritoneum, and lung, with plans to initiate Phase 2/3 trials in H1 2026.
US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings
U.S. stock futures were mixed ahead of the Federal Reserve's interest rate decision and key earnings reports from major tech companies. Investors are cautious as they await the Fed's policy announcement and guidance.